Stocks and Investing
Stocks and Investing
Fri, August 6, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Brian Abrahams Maintained (BCRX) at Hold with Increased Target to $16 on, Aug 6th, 2021
Brian Abrahams of RBC Capital, Maintained "BioCryst Pharmaceuticals, Inc." (BCRX) at Hold with Increased Target from $13 to $16 on, Aug 6th, 2021.
Brian has made no other calls on BCRX in the last 4 months.
There is 1 other peer that has a rating on BCRX. Out of the 1 peers that are also analyzing BCRX, 0 agree with Brian's Rating of Hold.
This is the rating of the analyst that currently disagrees with Brian
- Brian Cheng of "Cantor Fitzgerald" Initiated at Buy and Held Target at $21 on, Tuesday, August 3rd, 2021
Contributing Sources